Current treatment of chronic HBV infection: An Asian-Pacific perspective

被引：1
作者：
Liaw Y.-F. [1 ]
Chien R.-N. [1 ]
机构：
[1] Chang Gung Memorial Hospital and University, Taipei
来源：
Current Hepatitis Reports | 2009年 / 8卷 / 4期
关键词：
Chronic Hepatitis; Entecavir; HBeAg Seroconversion; Adefovir Dipivoxil; HBeAg Seroconversion Rate;
D O I：
10.1007/s11901-009-0022-x
中图分类号：
学科分类号：
摘要：
Chronic hepatitis B virus (HBV) infection is a major global health problem with potential adverse sequelae including liver cirrhosis and hepatocellular carcinoma. Of more than 350 million chronic HBV carriers, 75% reside in the Asian-Pacific region, where most countries have low-income economies. Better understanding of the natural history and immunopathogenesis of chronic HBV infection and the invention of powerful antiviral agents have improved the therapeutic strategy. Guidelines issued by major liver associations are basically similar. However, each country in the Asian-Pacific region has specific problems. Because cost is a main concern, drugs with low genetic barrier to resistance are still widely used in these countries. Modifications needed to accommodate specific situations and problems include more stringent indications for drug therapy, starting therapy with the least expensive drug, and defining stopping rules even for hepatitis B e antigen-negative patients. © 2009 Springer Science+Business Media, LLC.
引用
收藏
页码：154 / 160
页数：6
相关论文
共 55 条
  • [11] Kao J.H., Role of viral factors in the natural course and therapy of chronic hepatitis B, Hepatol Int, 1, pp. 415-430, (2007)
  • [12] Hui C.-K., Leung N., Yuen S.-T., Zhang H.-Y., Leung K.-W., Lu L., Cheung S.K.F., Wong W.-M., Lau G.K., Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase, Hepatology, 46, 2, pp. 395-401, (2007)
  • [13] Hsu Y.-S., Chien R.-N., Yeh C.-T., Sheen I.-S., Chiou H.-Y., Chu C.-M., Liaw Y.-F., Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B, Hepatology, 35, 6, pp. 1522-1527, (2002)
  • [14] Chu C.-M., Liaw Y.-F., Hepatitis B virus-related cirrhosis: Natural history and treatment, Seminars in Liver Disease, 26, 2, pp. 142-152, (2006)
  • [15] Chen Y.C., Chu C.M., Yeh C.T., Liaw Y.F., Natural course following the onset of cirrhosis in patients with chronic hepatitis B: A long-term follow-up study, Hepatol Int, 1, pp. 267-273, (2007)
  • [16] Chen C.-J., Yang H.-I., Su J., Jen C.-L., You S.-L., Lu S.-N., Huang G.-T., Iloeje U.H., Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level, Journal of the American Medical Association, 295, 1, pp. 65-73, (2006)
  • [17] Iloeje U.H., Yang H.-I., Su J., Jen C.-L., You S.-L., Chen C.-J., Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130, 3, pp. 678-686, (2006)
  • [18] Yang H.I., Yeh S.H., Chen P.J., Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma, J Natl Cancer Inst, 100, pp. 1134-1143, (2008)
  • [19] Chu C.-M., Liaw Y.-F., Chronic hepatitis B virus infection acquired in childhood: Special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion, Journal of Viral Hepatitis, 14, 3, pp. 147-152, (2007)
  • [20] Liaw Y.F., Hepatitis B virus replication and liver disease progression: The impact of antiviral therapy, Antivir Ther, 11, pp. 669-679, (2006)
123456